Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Heavy metal or compound thereof
Reexamination Certificate
2005-01-11
2005-01-11
Pak, John (Department: 1616)
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Heavy metal or compound thereof
C424S646000, C424S647000, C424S663000, C424S677000, C424S678000, C424S679000, C424S680000, C424S681000, C424S682000, C424S686000, C424S687000, C424S692000, C424S693000, C424S696000, C424S697000, C424S717000, C424S722000, C514S023000, C514S184000, C514S460000, C514S502000, C514S557000, C514S814000, C604S005040, C604S029000, C210S646000, C210S647000
Reexamination Certificate
active
06841172
ABSTRACT:
The invention relates to methods and compositions for delivering iron to an iron-deficient patient, more particularly, to methods whereby an iron complex comprising divalent or trivalent ionic iron complexed with one or more low molecular weight anions is administered to a patient by transfer from dialysate. A complex selected according to the invention is non-polymeric; soluble in an aqueous medium; chemically stable, thereby preventing the dissociation of iron ions from the anions under conditions according to the invention; and can be well absorbed into blood and the living body. Also provided are dialysate compositions including therein an iron complex selected according to the invention, and dialysate concentrates which may be diluted to yield an inventive dialysate composition.
REFERENCES:
patent: 3686397 (1972-08-01), Muller
patent: 3734851 (1973-05-01), Matsumura
patent: 3911915 (1975-10-01), Seifter et al.
patent: 4038413 (1977-07-01), Suschitzky et al.
patent: 4167564 (1979-09-01), Jensen
patent: 4315942 (1982-02-01), Corden
patent: 4581141 (1986-04-01), Ash
patent: 4659697 (1987-04-01), Tanaka
patent: 4732889 (1988-03-01), Cynshi et al.
patent: 4756838 (1988-07-01), Veltman
patent: 4810695 (1989-03-01), Conti et al.
patent: 4834983 (1989-05-01), Hider et al.
patent: 4970079 (1990-11-01), Hem et al.
patent: 5028411 (1991-07-01), Callingham et al.
patent: 5063205 (1991-11-01), Peters et al.
patent: 5108767 (1992-04-01), Mulchandani et al.
patent: 5177068 (1993-01-01), Callingham et al.
patent: 5277820 (1994-01-01), Ash
patent: 5336506 (1994-08-01), Josephson et al.
patent: 6689275 (2004-02-01), Gupta
patent: 0612528 (1994-08-01), None
patent: 2 177 021 (1987-01-01), None
patent: WO 982934 (1998-07-01), None
Martindale The Extra Pharmacopoeia, 13th edition, The Pharmaceutical Press, London, 1993, pages 976, 1596.*
Medline Accession No. 70113694, 1969.*
Medline Accession No. 76201043.*
Bastani, M.D., B and Gulley, R.N.S.,Intraperitoneal Iron-Dextran As A Potential Route of Iron Therapy in CAPD Patients,PDI November 1996, vol. 16, No. 6, pp. 648-648.*
Galletti, Pierre M., Colton, Clark K. and Lysaght, Michael J.,Artificial Kidney,The Biomedical Engineering Handbook, Ch. 126, pp. 1898-1922 (Date unavailable).*
Lysaght, Michael J. and Moran, John,Peritoneal Dialysis Equipment,The Biomedical Engineering Handbook, Ch. 127, pp. 1223-1935 (Date unavailable).*
Allegra A. Mengozzi G, Vasile A. Iron Deficiency in Maintenance Hemodialysis Patents: Assessment of Diagnosis Criteria and of Three Different Iron Treatments. Nephron 1991: 57:175-182.
Basta, SS, Soekirman MS, Karyadi D, Scrimshaw NS. Iron Deficiency Anemia and the Productivity of Adult Males in Indoneisa. The American Journal of Clinical Nutrition 32: April 1979, pp. 916-925.
Berner LA, Miller DD, VanCampen D. Availability to Rats of Iron in Ferric Hydroxide Polymers. 1042-1049. Date unknown. (Presented at the 68thAnnual Meeting of the Federation of American Societies for Experimental Biology, Apr. 1-6, 1984, St. Louis, Mo.
Best CH. The Physiological Basis of Medical Practice. The Williams & Wilkins Company, Third Edition, Baltimore, 1943, pp. 94-99.
BLUTAL® Injection (Chondroitin sulfate-iron colloid) Product Information. Date unknown.
Brown EB, Moore CV, Reynafarje C, Smith DE. Intravenously Administered Saccharated Iron Oxide in the Treatment of Hypochromic Anemia. JAMA, Nov. 25, 1950, 1084-1089.
Byrd TF, Horwitz MA. Lactoferrin Inhibits or Promotes Legionella Pneumophila Intracellular Multiplication in Nonactivated and Interferon Gamma-Activated Human Monocytes Depending Upon Its Degree of Iron Saturation. J. Clin. Invest. Vol. 88, October 1991, 1103-1112.
Calvar C, Mata D, Alonso C, Ramos B, Lopez de Novales E. Intravenous Administration of Iron Gluconate During Haemodialysis. Nephrol Dial Transplant (1997) 12:574-575.
Carver FJ, Frieden E. Factors Affecting the Adenosine Triphosphate Induced Release of Iron from Transferrin. Biochemistry, Vol 17, No. 1, 1978 167-172.
Cheuk MS, Loh TT, Hui YV, Keung WM. Kinetics of Pyrophosphate Induced Iron Release From Differic Ovotransferrin. Journal of Inorganic Biochemistry 29, 301-311 (1987).
Cook, JD, Skikne BS, Baynes RD. Iron Deficiency: The Global Perspective. Progress in Iron Research Edited by C. Hersnko et al. Plenum Press, New York, 1994, pp. 219-228.
Ersley AJ. Erythropoietin. NEJM, Vol 324, No. 19, May 8, 1991. pp. 1339-1344.
Eschbach JW, Cook JD, Scribner BH, Finch CA. Iron Balance in Hemodialysis Patients. Annals of Internal Medicine 87: December 1977, 710-713.
Feeley JC, Gorman GW, Weaver RE, Mackel DC, Smith HW. Primary Isolation Media for Legionnaires Disease Bacterium. Journal of Clinical Microbiolog, September 1978, Vol. 8, No. 3, pp. 320-325.
Fishbane S, Frei GL, Maesaka J. Reduction in Recombinant Human Erythropoietin Doses by the Use of chronic Intravenous Iron Supplementation. American Journal of Kidney Diseases, Vol. 26, No. 1, 1995, pp. 41-46.
Fishbane S. Lynn RI. The Utility of Zinc Protoporphyrin for Predicting the Need for Intravenous Iron Therapy in Hemodialysis Patients. American Journal of Kidney Diseases, Vol. 25, No. 3 (March), 1995: pp. 426-432.
Fishbane S, Ungureanu VD, Maesaka JK, Kaupke CJ, Lim V, Wish J. The Safety of Intravenous Iron Dextran in Hemodialysis Patents. American Journal of Kidney Diseases Vol. 28, No. 4 (October), 1996: pp. 529-534.
Fleisch H. Bisaz S. Mechanism of Calcification: Inhibitory Role of Pyrophosphate. Nature, Vol. 195, No. 4844, Sep. 1, 1962, p. 911.
Fleisch H. Bisphosphonates—Preclinical. Bisphosphonates in Bone Disease From the Laboratory to the Patient. Second Edition. The Parthenon Publishing Group, Inc. 1995, pp. 31-34.
Goetsch AT, Moore CV, Minnich V. Observations of the Effect of Massive Doses of Iron Given Intravenously to Patents With Hypochromic Anemia. From the Department of Internal Medicine, Washington University School of Medicine, St. Louis. Date Unknown.
Hamstra RD, Block MH, Schocket AL. Intravenous Iron Dextran in Clinical Medicine. JAMA, May 2, 1980, Vol. 243, No. 17, 1726-1731.
Harken AH, Simson MB, Haselgrove J, Wetstein L, Harden III WR, Barlow CH. Early Ischemia After Complete Coronary Ligation In The Rabbit, Dog, Pig and Monkey. Am J Physiol 241 (Haert Circ Physiol 10): H202-H210, 1981.
Harrett RF, Furness DE, Burn J, Whittaker P, Lanen JR, Cook JD. Am J Clin Nutr. (1989):49:1274-82.
Hatton RC, Portales IT, Finlay A, Ross EA. Removal of Iron Dextran by Hemodialysis: An In Vitro Study. American Journal of Kidney Diseases, Vol. 26, No. 2 (August), 1995: pp. 327-330.
Heath CW, Strauss MB, Castle WB. Quantitative Aspects of Iron Deficiency in Hypochromic Anemia. From the Thorndike Memorial Laboratory, Second and Fourth Medical Services (Harvard Medical School, Boston) Date Unknown (received for publication Aug. 1, 1932).
Ifudu O, Feldman J, Friedman EA. The Intensity of Hemodialysis and the Response to Erythropoietin in Patients With End-Stage Renal Disease. NEJM, Feb. 15, 1996, pp. 420-425.
Jacobs K, Shoemaker C, Rudersdorf R, Neill SD, Kaufman RJ, Mufson A, Seehra J, Jones SS, Hewick R, Fritsch EF, Kawakita M, Shimizu T, Miyake T. Isolation and Characterization of Genomic and cDNA Clones of Human Erythropoietin. Nature, Vol. 313, Feb. 28, 1985, pp. 806-810.
Javaid H, Haschke F, Pietschnig B, Schuster E, Huemer, Shebaz A, Ganesh P, Steffan I, Hurrel R, Secretin M C. Interactions Between Infections, Malnutrition and Inronnutritional Status in Pakistani Infacts. Acta Prediatr Scand Suppl 374:141, 1991.
Jung A, Russell RGG, Bisaz S, Morgan DB, Fleisch H. Fate of Intravenously Injected Pyrophosphate-32P in Dogs. American Journal of Physiology, Vol. 218, No. 6, June 1970, pp. 1757-1764.
Kleiner MJ, Van Wyck DB, Kaupke CJ, Kirlin LF. The Role of Iron and Other Factors in Patients Unresponsive to Erythropoietin Therapy, Seminars in Dialysis, vol. 8, No. 1 (Jan-Feb) 1995 pp. 29-34.
Kolff WJ. First Clinical Experience With the Artificial Kidney. Annals of Internal Medicine, vol. 62, No. 3, March 1965, pp. 608-619.
Konopka K, Mareschal JC, Crichton RR. Iron Transfer From Transferrin to F
HemoCleanse, Inc.
Pak John
Woodard Emhardt Moriarty McNett & Henry LLP
LandOfFree
Method for iron delivery to a patient by transfer from... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for iron delivery to a patient by transfer from..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for iron delivery to a patient by transfer from... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3405520